Skip to main content
SpringerLink
Log in

MDCT Versus MRI Assessment of Tumor Response After Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma

  • Clinical Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

The purpose of this study was to compare the ability of multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) to evaluate treatment results after transarterial chemoembolization (TACE), with a special focus on the influence of Lipiodol on calculation of tumor necrosis according to EASL criteria. A total of 115 nodules in 20 patients (17 males, 3 females; 69.5 ± 9.35 years) with biopsy-proven hepatocellular carcinoma were treated with TACE. Embolization was performed using a doxorubicin-Lipiodol emulsion (group I) or DC Beads loaded with doxorubicin (group II). Follow-up included triphasic contrast-enhanced 64-row MDCT (collimation, 0.625 mm; slice, 3 mm; contrast bolus, 120 ml iomeprol; delay by bolus trigger) and contrast-enhanced MRI (T1 native, T2 native; five dynamic contrast-enhanced phases; 0.1 mmol/kg body weight gadolinium-DTPA; slice thickness, 4 mm). Residual tumor and the extent of tumor necrosis were evaluated according to EASL. Contrast enhancement within tumor lesions was suspected to represent vital tumor. In the Lipiodol-based TACE protocol, MDCT underestimated residual viable tumor compared to MRI, due to Lipiodol artifacts (23.2% vs 47.7% after first, 11.9% vs 31.2% after second, and 11.4% vs 23.7% after third TACE; p = 0.0014, p < 0.001, and p < 0.001, respectively). In contrast to MDCT, MRI was completely free of any artifacts caused by Lipiodol. In the DC Bead-based Lipiodol-free TACE protocol, MRI and CT showed similar residual tumor and rating of treatment results (46.4% vs 41.2%, 31.9 vs 26.8%, and 26.0% vs 25.6%; n.s.). In conclusion, MRI is superior to MDCT for detection of viable tumor residuals after Lipiodol-based TACE. Since viable tumor tissue is superimposed by Lipiodol artifacts in MDCT, MRI is mandatory for reliable decision-making during follow-up after Lipiodol-based TACE protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156

    Article  PubMed  CAS  Google Scholar 

  2. Liu Q, Song Y, Zhou Y et al (2006) A useful agent for chemoprevention of hepatocellular carcinoma? Cancer Biol Ther 5:1674–1676

    PubMed  CAS  Google Scholar 

  3. Lodato F, Mazzella G, Festi D et al (2006) Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 12:7239–7249

    PubMed  Google Scholar 

  4. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  PubMed  CAS  Google Scholar 

  5. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524

    Article  PubMed  Google Scholar 

  6. Llovet JM, Fuster J, Bruix J (2004) Barcelona-Clínic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10:115–120

    Article  Google Scholar 

  7. Cillo U, Bassanello M, Vitale A et al (2004) The critical issue of hepatocellular carcinoma prognostic classification: Which is the best tool available? J Hepatol 40:124–131

    Article  PubMed  Google Scholar 

  8. Cillo U, Vitale A, Grigoletto F et al (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44:723–731

    Article  PubMed  Google Scholar 

  9. De Giorgio M, Fagiuoli S (2007) Management of hepatocellular carcinoma. Dig Dis 25:279–281

    Article  PubMed  Google Scholar 

  10. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442

    Article  PubMed  CAS  Google Scholar 

  11. Satake M, Uchida H, Arai Y et al (2008) Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. CardioVasc Interv Radiol 31:756–761

    Article  Google Scholar 

  12. Hihara T, Araki T, Kachi et al (1992) Dense parenchymal accumulation of Lipiodol after transarterial chemoembolization. Radiat Med 10:79–81

    PubMed  CAS  Google Scholar 

  13. Takayama T, Makuuchi M, Hirohashi S et al (1990) Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 336:1150–1153

    Article  PubMed  CAS  Google Scholar 

  14. Bruix J, Sherman M, Llovet JM et al (2001) EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430

    Article  PubMed  CAS  Google Scholar 

  15. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

  16. Padhani AR, Ollivier L (2001) The RECIST criteria: implications for diagnostic radiologists. Br J Radiol 74:983–986

    PubMed  CAS  Google Scholar 

  17. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236

    Article  PubMed  Google Scholar 

  18. Herber S, Biesterfeld S, Franz U et al (2008) Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. CardioVasc Interv Radiol 31:768–777

    Article  CAS  Google Scholar 

  19. Castrucci M, Sironi S, De Cobelli F et al (1996) Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization. Abdom Imaging 21:488–494

    Article  PubMed  CAS  Google Scholar 

  20. Semelka RC, Worawattanakul S, Mauro MA et al (1998) Malignant hepatic tumors: changes on MRI after hepatic arterial chemoembolization-preliminary findings. J Magn Reson Imaging 8:48–56

    Article  PubMed  CAS  Google Scholar 

  21. Kubota K, Hisa N, Nishikawa T et al (2001) Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 26:184–190

    Article  PubMed  CAS  Google Scholar 

  22. De Santis M, Alborino S, Tartoni PL et al (1997) Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol 7:10–16

    Article  PubMed  Google Scholar 

  23. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. CardioVasc Interv Radiol 30:6–25

    Article  Google Scholar 

  24. Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC Bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342

    Article  PubMed  Google Scholar 

  25. Johnson PJ, Kalayci C, Dobbs N et al (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13:120–127

    Article  PubMed  CAS  Google Scholar 

  26. Sultana S, Awai K, Nakayama Y et al (2007) Hypervascular hepatocellular carcinomas: bolus tracking with a 40-detector CT scanner to time arterial phase imaging. Radiology 243:140–147

    Article  PubMed  Google Scholar 

  27. Alba E, Valls C, Dominguez J et al (2008) Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am J Roentgenol 190:1341–1348

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Johannes Gutenberg-University of Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany

    Roman Kloeckner, Katja Oberholzer, Christoph Dueber & Michael B. Pitton

  2. Department of Transplantation and Hepatobiliary Pancreatic Surgery, Johannes Gutenberg-University of Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany

    Gerd Otto

  3. Department of Pathology, Johannes Gutenberg-University of Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany

    Stefan Biesterfeld

Authors
  1. Roman Kloeckner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerd Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Biesterfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katja Oberholzer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christoph Dueber
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael B. Pitton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roman Kloeckner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kloeckner, R., Otto, G., Biesterfeld, S. et al. MDCT Versus MRI Assessment of Tumor Response After Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 33, 532–540 (2010). https://doi.org/10.1007/s00270-009-9728-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-009-9728-y

Keywords

Search

Navigation